Comparative Pharmacology
Head-to-head clinical analysis: BENZACLIN versus STATICIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZACLIN versus STATICIN.
BENZACLIN vs STATICIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BENZACLIN (clindamycin 1% and benzoyl peroxide 5%) is a combination antibacterial agent. Clindamycin is a lincosamide antibiotic that binds to the 50S ribosomal subunit of bacteria, inhibiting protein synthesis and reducing Propionibacterium acnes growth. Benzoyl peroxide has bactericidal and keratolytic properties; it releases free radical oxygen species that oxidize bacterial proteins, decreasing P. acnes, and also causes drying and peeling of the skin.
STATICIN is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
Topical gel applied once or twice daily to affected areas. Each gram contains 1% clindamycin and 5% benzoyl peroxide.
500 mg orally every 12 hours for 7-14 days.
None Documented
None Documented
After topical application, plasma concentrations of clindamycin are negligible; the systemic half-life of clindamycin from absorbed fraction is approximately 2.5-3 hours in adults. However, due to minimal systemic absorption, the terminal half-life is not clinically relevant for topical therapy.
6-8 hours in adults with normal renal function; extends to 12-20 hours in moderate renal impairment (CrCl <30 mL/min).
Benzaclin (clindamycin 1% - benzoyl peroxide 5%) is a topical formulation; systemic absorption is minimal. After topical application, less than 1% of clindamycin is absorbed. Absorbed clindamycin is primarily excreted in urine (10% as active drug, 90% as metabolites) and feces (<5%). Benzoyl peroxide is metabolized to benzoic acid, which is conjugated and excreted in urine. Overall, renal excretion accounts for the majority of clearance of absorbed components.
Renal excretion of unchanged drug accounts for 70-80% of total clearance; biliary/fecal excretion accounts for 15-20%; <5% metabolized.
Category C
Category C
Topical Antibiotic
Topical Antibiotic